Compare Ginkgo Bioworks Holdings Inc (DNA) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Live Nation Entertainment, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.04 (market cap $590.53M), while Live Nation Entertainment, Inc. trades at $179.4 (market cap $42.25B). The key difference: Live Nation Entertainment, Inc. is far larger — about 71.5× Ginkgo Bioworks Holdings Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | LYV | |
|---|---|---|
Market Cap | $590.53M | $42.25B |
Sector | Health | Industrials |
52-Week High | $16.14 | $186.59 |
52-Week Low | $5.48 | $125.61 |
Enterprise Value | $627.78M | $43.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Live Nation (LYV) trades at $183.25, up 1.92% with strong analyst support (88.6% buy ratings) and a $200.20 consensus target. The stock shows bullish technical signals with support at $178 and resistance at $185. Despite recent earnings misses, revenue grew to $25.2B in 2025, though net margins remain thin at 0.33% with negative ROE of -24.68%.
The outlook remains positive given strong concert demand and ticketing dominance, but elevated valuation (P/E 117.5) and regulatory scrutiny pose risks. Cash flow improved to $1.0B net in 2025, supporting growth investments. Institutional sentiment favors upside to price targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
